一种用于癌症疼痛控制的新型永久性外置硬膜外自控镇痛导管。

A new permanent exteriorized epidural catheter for narcotic self-administration to control cancer pain.

作者信息

DuPen S L, Peterson D G, Bogosian A C, Ramsey D H, Larson C, Omoto M

出版信息

Cancer. 1987 Mar 1;59(5):986-93. doi: 10.1002/1097-0142(19870301)59:5<986::aid-cncr2820590523>3.0.co;2-c.

DOI:10.1002/1097-0142(19870301)59:5<986::aid-cncr2820590523>3.0.co;2-c

Abstract

The lack of an available exteriorized permanent epidural catheter led to the application of the Broviac catheter technology to the development of an epidural catheter. The resulting three-piece silicone-rubber catheter system allows specific spinal-level location of the catheter tip from a lumbar entry site, and exteriorization for ease of self-administration. Fifty-five cancer patients with metastatic disease and intractable pain received 58 catheters. No catheter infections were found during 3891 catheter-days of use, and only 18 minor side effects were noted, with no respiratory depression observed. Hospitalizations for pain control was decreased by 90% after catheter placement. Therefore, the authors recommend early placement of this silicone-rubber epidural catheter to control pain unrelieved by oral analgesics.

摘要

由于缺乏可用的外置永久性硬膜外导管，促使人们将 Broviac 导管技术应用于硬膜外导管的研发。由此产生的三件式硅橡胶导管系统能够使导管尖端从腰椎穿刺部位精准定位到特定的脊髓节段，并可外置以便于自我给药。55 名患有转移性疾病和顽固性疼痛的癌症患者接受了 58 根导管。在 3891 个导管使用日期间未发现导管感染，仅记录到 18 例轻微副作用，未观察到呼吸抑制。放置导管后，因疼痛控制而住院的人数减少了 90%。因此，作者建议早期放置这种硅橡胶硬膜外导管，以控制口服镇痛药无法缓解的疼痛。